It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
in vivo pharmacokinetic (PK) and pharmacodynamic (PD) studies designed to deliver high-quality, decision-enabling data. Combined with quantitative bioanalysis utilizing UPLC-MS/MS platforms with rigorous method development tailored to diverse analytes assessed against predefined acceptance criteria aligned with current bioanalytical guidelines delivers high-quality, reproducible data that supports confident decision-making and accelerates progression through the drug development pipeline.
Understanding a compound’s PK and PD profile is fundamental to evaluating its therapeutic potential. At Sygnature Discovery, we offer fully integrated, non-GLP rodent in vivo studies designed to deliver high quality, decision-enabling data.
By combining pharmacokinetics, pharmacology, formulation and bioanalytical expertise, we ensure studies reflect real-world drug delivery conditions and deliver actionable insights to drive early development forward.
in vivo Pharmacokinetics and Pharmacodynamics
Our rodent in vivo PK and PK/PD studies determine ADME properties and deliver key parameters such as clearance, volume of distribution, half-life, and bioavailability, alongside insight into candidate efficacy. Every study can be tailored to your compound’s characteristics and development goals, with expert interpretation and reporting that translate complex findings into practical guidance for early safety and efficacy assessments.
Why Choose Sygnature Discovery for in vivo PK & PD Support?
Sygnature Discovery offers a fully integrated platform for in vivo PK and PD studies, underpinned by deep scientific expertise and state-of-the-art analytical capabilities. Our team designs and executes tailored studies to characterize ADME and Sygnature Discovery offers a fully integrated platform for in vivo PK and PD studies, underpinned by deep scientific expertise and state-of-the-art analytical capabilities. Our team designs and executes tailored studies to characterize ADME and pharmacological response, generating high-quality exposure and efficacy data that enable early-stage decision-making.
We combine advanced method development with robust quantitative bioanalysis, supporting a wide range of analytes-including lipophilic steroids, peptides, endogenous biomarkers, and highly polar compounds- across complex biological matrices such as plasma, blood, urine, bile, and tissues. Using UPLC-MS/MS and hydrophilic interaction liquid chromatography (HILIC), we deliver sensitive, selective, and reproducible quantification.
Bifunctional degraders bind and degrade proteins via ubiquitin ligase, despite breaking bRo5 rules. Translating in vitro DMPK data to in vivo performance remains a challenge. At Sygnature Discovery, we provide tailored assays and expertise to support projects involving these compounds. Read more in the poster.
Explore cytokine dynamics in inflammation with our insightful poster, featuring advanced quantification techniques. Download for invaluable insights in immunology and drug discovery.
Learn from Dr Phillip MacFaul, Sygnature Discovery’s Principal Scientist in DMPK about measuring EPSA in bifunctional degraders.
Blog
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Integrated solid form and formulation strategies reduce risk, improve stability and solubility, and accelerate progression from candidate selection to clinic.
Validated in vivo models deliver clinically relevant data across therapeutic areas, accelerating confident decisions and reducing risk in drug development.
